Skip to main content

Table 2 Clinical efficacy of NGX-4010 in all patients with PHN

From: Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgia

NPRS Scores

NGX-4010

(n = 102)

Control

(n = 53)

P-value

Baseline, LS mean (SE)

5.4 (0.16)

5.3 (0.22)

 

   95% CI

5.12, 5.73

4.87, 5.72

 

Change, mean (SE)

   

   Baseline to weeks 2 to 8

-1.8 (0.20)

-1.6 (0.27)

0.462

   95% CI

-2.23, -1.45

-2.13, -1.05

 

   Baseline to weeks 2 to 12

-1.8 (0.20)

-1.7 (0.28)

0.750

   95% CI

-2.25, -1.45

-2.29, -1.18

 

Percent Change, mean (SE)

   

   Baseline to weeks 2 to 8

-36.5 (3.68)

-29.9 (5.10)

0.296

   95% CI

-43.72, -29.19

-39.94, -19.78

 

   Baseline to weeks 2 to 12

-36.6 (3.75)

-32.3 (5.21)

0.509

   95% CI

-44.02, -29.19

-42.63, -22.05

 

Patients with ≥ 30% reduction, %

   

   Baseline to weeks 2 to 8

49

45

0.574

   Baseline to weeks 2 to 12

49

49

0.956

Patients with ≥ 50% reduction, %

   

   Baseline to weeks 2 to 8

36

36

0.930

   Baseline to weeks 2 to 12

39

36

0.628

PGIC

   

   Improved (very much, much)

   

   Week 4, n

100

49

 

N (%)

40 (40)

19 (39)

1.0000

   Week 8, n

91

43

 

N (%)

43 (47)

14 (33)

0.1351

   Week 12, n

95

50

 

N (%)

41 (43)

15 (30)

0.1518